- United States
- /
- Biotech
- /
- NasdaqGM:ACIU
What Do Analysts Think About AC Immune SA's (NASDAQ:ACIU) Future?
Analysts' outlook for the coming year seems pessimistic, with earnings becoming even more negative, generating -CHF49.85M in 2019. Moreover, earnings are predicted to fall off in the following year, declining to -CHF56.20M in 2020 and -CHF98.18M in 2021.
Although it is useful to understand the growth year by year relative to today’s value, it may be more beneficial to analyze the rate at which the earnings are moving on average every year. The pro of this method is that we can get a bigger picture of the direction of AC Immune's earnings trajectory over the long run, irrespective of near term fluctuations, be more volatile. To calculate this rate, I've inserted a line of best fit through analyst consensus of forecasted earnings. The slope of this line is the rate of earnings growth, which in this case is 0.85%. This means that, we can anticipate AC Immune will grow its earnings by 0.85% every year for the next couple of years.
Next Steps:
For AC Immune, there are three relevant factors you should look at:
- Financial Health: Does it have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.
- Future Earnings: How does ACIU's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
- Other High-Growth Alternatives: Are there other high-growth stocks you could be holding instead of ACIU? Explore our interactive list of stocks with large growth potential to get an idea of what else is out there you may be missing!
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Simply Wall St analyst Simply Wall St and Simply Wall St have no position in any of the companies mentioned. This article is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
About NasdaqGM:ACIU
AC Immune
A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
Flawless balance sheet and good value.
Market Insights
Community Narratives


